Two new lawsuits allege Dexcom G7 monitors malfunctioned in children, causing diabetic ketoacidosis and hypoglycemic seizures ...

Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go ...

Despite growing awareness of CGM and GLP-1 use for type 2 diabetes management, Dexcom’s report found that lack of awareness ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: ...

DexCom develops and markets continuous glucose monitoring (CGM) systems, a type of device that continuously tracks blood sugar levels. The technology isn't exactly new anymore, and it has enjoyed ...

RBC lifted its target from USD 90 to USD 105 on October 1, 2026, while DexCom's Q2 adjusted EPS reached USD 0.70. The shares last stood at USD 85.36 on October 2, 2026, down 1.01 percent.

Dexcom ( ) has issued an announcement. On September 10, 2026, Dexcom ’s board appointed Executive Vice President and Chief Financial Officer Jereme Sylvain to the expanded role ...

Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...

DexCom has released its “State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd ...

DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...

DexCom stock (ISIN US2521311074) closed at USD 86.62 on Nasdaq on September 25, 2026, down 0.97 percent from the prior close.

DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking ...